Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP

Developing World Bioethics 13 (2):87-94 (2013)
  Copy   BIBTEX

Abstract

The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks – either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV – expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 74,662

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Analytics

Added to PP
2013-06-01

Downloads
56 (#209,212)

6 months
1 (#419,921)

Historical graph of downloads
How can I increase my downloads?